JPMorgan and Mizuho Raise Humana (HUM) Price Targets as Managed Care Outlook Improves

JPMorgan and Mizuho Raise Humana (HUM) Price Targets as Managed Care Outlook Improves Vardah Gill Mon, June 15, 2026 at 7:11 AM GMT+2 1 min read HUM Humana Inc. (NYSE: HUM ) is included among Billionaire Larry Robbins’ 10 Dividend Stock Picks . JPMorgan and Mizuho Raise Humana (HUM) Price Targets as Managed Care Outlook Improves On June 8, JPMorgan analyst Lisa Gill raised the firm’s price target on Humana Inc.

(NYSE:HUM) to $316 from $214 and maintained a Neutral rating on the shares. The firm updated its healthcare services models. The same day, Mizuho raised its price recommendation on Humana to $390 from $335.

It reiterated an Outperform rating on the stock. Mizuho believes the managed care sector is moving into a “more stable and predictable” policy environment. According to the analyst, the scale and frequency of policy-related surprises are likely to ease from the elevated levels seen over the past three years.

That shift could allow investors to focus more on company fundamentals, pricing recovery, and the sector’s underlying earnings power, the analyst said in a research note. Mizuho also increased price targets across the managed care sector to reflect what it sees as a more stable regulatory and legislative backdrop. Humana Inc.

(NYSE:HUM) provides Humana insurance services and CenterWell health care services. The company operates through two segments: Insurance and CenterWell. While we acknowledge the potential of HUM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.

If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the   best short-term AI stock . READ NEXT:  10 Best S&P 500 Dividend Stocks to Buy Right Now  and  10 Best Value Dividend Stocks to Buy Now According to Warren Buffett Disclosure: None. Follow Insider Monkey on Google News .